공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

중추신경계 치료제 시장 규모, 점유율, 동향 분석 : 질환(신경혈관 질환, CNS 외상, 정신건강, 신경변성질환, 감염증), 지역별 예측(2021-2028년)

Central Nervous System Therapeutic Market Size, Share & Trends Analysis Report By Disease (Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases), By Region, And Segment Forecasts, 2021 - 2028

리서치사 Grand View Research, Inc.
발행일 2021년 02월 상품 코드 989704
페이지 정보 영문 120 Pages
가격
US $ 5,950 ₩ 6,725,000 Unprintable PDF (Single User License)
US $ 6,950 ₩ 7,855,000 Printable PDF (5-User License)
US $ 8,950 ₩ 10,116,000 Printable PDF (Enterprise License)


중추신경계 치료제 시장 규모, 점유율, 동향 분석 : 질환(신경혈관 질환, CNS 외상, 정신건강, 신경변성질환, 감염증), 지역별 예측(2021-2028년) Central Nervous System Therapeutic Market Size, Share & Trends Analysis Report By Disease (Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases), By Region, And Segment Forecasts, 2021 - 2028
발행일 : 2021년 02월 페이지 정보 : 영문 120 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 중추신경계 치료제 시장 규모는 예측 기간 중 7.4%의 CAGR로 추이하며, 2028년에는 2050억 달러 규모로 성장할 것으로 예측됩니다. 미충족 요구의 존재 및 질병 부담의 경감을 위한 정부 구상 등의 요인이 이 시장의 성장을 촉진할 전망입니다.

세계의 중추신경계 치료제 시장을 조사했으며, 시장의 정의와 개요, 시장 성장에 대한 각종 영향요인 분석, 역학적 동향, 파이프라인 분석, 시장 규모의 추이·예측, 질환·지역/주요 국가 등 각종 부문별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.

제1장 조사 방법·조사 범위

제2장 개요

제3장 시장 가변 요인·동향·전망

  • 시장 세분화
  • 보급·성장 전망 지도제작
  • 규제 프레임워크
  • 파이프라인 분석
  • 역학 연구

제4장 산업 전망

  • 시장 성장 촉진요인 분석
  • 시장 성장 저해요인 분석

제5장 사업 환경 분석

  • SWOT 분석
  • Porter의 산업 분석

제6장 경쟁 분석

  • 주요 거래·전략적 제휴
  • 주요 기업·최근 개발·영향 분석
  • 공개 기업
  • 비공개 기업

제7장 시장 예측·동향 분석 : 질환별

  • 신경혈관 질환
  • 정신건강
    • 불안장애
    • 기분 장애
    • 간질
    • 정신병성 장애
    • 기타
  • 변성질환
    • 알츠하이머병
    • 파킨슨병
    • 다발성 경화증
    • 헌팅턴병
    • 근위축성 측색 경화증
    • 기타
  • CNS 외상
  • 감염증
  • CNS 암
  • 기타

제8장 시장 예측·동향 분석 : 지역·주요 국가별

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 영국
    • 스페인
    • 프랑스
    • 이탈리아
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 한국
    • 호주
  • 라틴아메리카
    • 브라질
    • 멕시코
    • 아르헨티나
  • 중동·아프리카
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트

제9장 기업 개요

KSA 21.02.23

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 Pipeline Analysis
  • Table 3 Epidemiology
  • Table 4 North America CNS Therapeutics Market, By Country, 2017 - 2028 (USD Million)
  • Table 5 North America CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 6 U.S. CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 7 Canada CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 8 Europe CNS Therapeutics Market, By Country, 2017 - 2028 (USD Million)
  • Table 9 Europe CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 10 U.K. CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 11 France CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 12 Spain CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 13 Italy CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 14 Germany CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 15 Asia Pacific CNS Therapeutics Market, By Country, 2017 - 2028 (USD Million)
  • Table 16 Asia Pacific CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 17 Japan CNS Therapeutics Market, By Disease 2017 - 2028 (USD Million)
  • Table 18 China CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 19 India CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 20 Australia CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 21 South Korea CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 22 Latin America CNS Therapeutics Market, By Country, 2017 - 2028 (USD Million)
  • Table 23 Latin America CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 24 Brazil CNS Therapeutics Market, By Disease 2017 - 2028 (USD Million)
  • Table 25 Mexico CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 26 Argentina CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 27 Middle East & Africa CNS Therapeutics Market, By Country, 2017 - 2028 (USD Million)
  • Table 28 Middle East & Africa CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 29 South Africa CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 30 Saudi Arabia CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 31 UAE CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)

List of Figures

  • Fig. 1 CNS therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 CNS therapeutics market snapshot
  • Fig. 10 CNS therapeutics market driver impact
  • Fig. 11 CNS therapeutics market restraint impact
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 SWOT analysis, by factor (political & legal economic and technological)
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 CNS therapeutics market: Disease outlook and key takeaways
  • Fig. 16 CNS therapeutics market: Disease movement analysis
  • Fig. 17 Disease segment dashboard
  • Fig. 18 Neurovascular diseases market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 19 CNS trauma market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 20 Mental health market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 21 Anxiety disorders market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 22 Epilepsy market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 23 Mood disorders market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 24 Psychotic disorders market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 25 Other mental health market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 26 Neurodegenerative diseases market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 27 Alzheimer's disease market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 28 Parkinson's disease market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 29 Multiple sclerosis market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 30 Huntington's disease market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 31 Amyotrophic lateral sclerosis market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 32 Other neurodegenerative diseases market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 33 Infectious diseases market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 34 CNS cancer market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 35 Others market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 36 CNS therapeutics market: Regional outlook and key takeaways
  • Fig. 37 Regional outlook, 2020 & 2028 (USD Million)
  • Fig. 38 Regional market dashboard
  • Fig. 39 North America
  • Fig. 40 North America market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 41 U.S.
  • Fig. 42 U.S. market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 43 Canada
  • Fig. 44 Canada market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 45 Europe
  • Fig. 46 Europe market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 47 Germany
  • Fig. 48 Germany market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 49 U.K.
  • Fig. 50 U.K. market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 51 Spain
  • Fig. 52 Spain market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 53 France
  • Fig. 54 France market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 55 Italy
  • Fig. 56 Italy market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 57 Asia Pacific
  • Fig. 58 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 59 Japan
  • Fig. 60 Japan market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 61 China
  • Fig. 62 China market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 63 India
  • Fig. 64 India market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 65 South Korea
  • Fig. 66 South Korea market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 67 Australia
  • Fig. 68 Australia market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 69 Latin America
  • Fig. 70 Latin America market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 71 Brazil
  • Fig. 72 Brazil market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 73 Mexico
  • Fig. 74 Mexico market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 75 Argentina
  • Fig. 76 Argentina market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 77 Middle East & Africa
  • Fig. 78 Middle East & Africa market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 79 South Africa
  • Fig. 80 South Africa market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 81 UAE
  • Fig. 82 UAE market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 83 Saudi Arabia
  • Fig. 84 Saudi Arabia market estimates and forecast, 2017 - 2028 (USD Million)

Central Nervous System Therapeutic Market Growth & Trends

The global central nervous system therapeutic market size is expected to reach USD 205.0 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.4% from 2021 to 2028. High unmet medical needs and government initiatives to reduce the disease burden are driving the market for central nervous system (CNS) therapeutic over the forecast period. According to WHO, the global economy loses due to depression and anxiety is more than USD 1 trillion per year and rising patient base of mental health globally is expected to increase the economy loses by USD 16 trillion in 2030.

The market holds strong future growth opportunities and major players are adopting different marketing strategies such as new product development, collaborations, geographic expansion, mergers and acquisitions, and new product approval, to strengthen their positions. In February 2020, Biogen announced the investment in Sangamo's zinc finger platform to develop therapies for Alzheimer's disease and other neurological diseases. Similarly, the company has an agreement with Ionis Pharmaceutical for the development of drug candidates applicable across a wide range of neurological diseases.

Presence of strong pipeline products by major pharmaceutical companies such as Biogen, H. Lundbeck A/S, Eli Lilly and Company, and others are expected to accelerate market growth over the forecast period. Besides, other pharmaceutical companies are also actively involved in the development of novel therapies and investing heavily to develop effective therapeutics for the treatment of CNS associated diseases.

Most of the late phase development drugs are for the treatment of neurodegenerative disorders such as Alzheimer's disease, multiple sclerosis, Parkinson's disease, and amyotrophic lateral sclerosis. The drug candidates such as aducanumab, brexpiprozole, evobrutinib, solanezumab are some of the potential drugs that could be commercialized in the next five to eight years for the treatment of various indication of neurodegenerative disorders. Apart from neurodegenerative diseases, migraine, schizophrenia, and epilepsy are the major CNS disease indications that have potential drug candidates in pipeline.

The cancer segment is expected to witness the fastest growth rate over the forecast period. Increasing prevalence, high mortality rate, and rising demand for effective treatment are expected to fuel the growth of the market for CNS therapeutic. According to National Cancer Institute estimates, the number of new cases of CNS cancers was 23,890 whereas the number of deaths was 18,020 in the U.S. in 2020.

Pharmaceutical companies are adopting strategies such as product development, merger and acquisition, and collaboration to strengthen their position in market. For instance, Biogen has signed agreements with Ionis Pharmaceuticals, Atalanta Therapeutics, and Sangamo Therapeutics to develop novel therapeutics for the treatment of different disease indications of the central nervous system. Similarly, in January 2020, the CNS Pharmaceuticals has entered into a licensing agreement with MD Anderson Cancer Center to investigate WP1244, a designed DNA-binding agent to cross the blood-brain barriers for the potential treatment of brain cancers.

Central Nervous System Therapeutic Market Report Highlights

  • The neurodegenerative diseases segment accounted for the largest revenue share of nearly 40.0% in 2020 and is anticipated to maintain its dominance over the forecast period
  • Pipeline candidates such as aducanumab, brexpiprozole, evobrutinib, solanezumab are anticipated to drive the neurodegenerative disorder segment from 2021 to 2028
  • The CNS cancer segment is expected to witness the fastest growth rate over the forecast period. Increasing demand for effective treatment is expected to drive the segment
  • In Asia Pacific, the market is estimated to witness the fastest growth over the coming years owing to the increase in treatment rate and betterment of healthcare infrastructure in the region
  • North America held a majority of share in 2020 due to high awareness level in the region and better reimbursement scenario

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Research Methodology
  • 1.2 Research Assumptions
    • 1.2.1 Estimates and Forecast Timeline
  • 1.3 Research Methodology
  • 1.4 Information Procurement
    • 1.4.1 Purchased Database
    • 1.4.2 GVR's Internal Database
    • 1.4.3 Secondary Sources
    • 1.4.4 Primary Research
    • 1.4.5 Details of Primary Research
  • 1.5 Information or Data Analysis
    • 1.5.1 Data Analysis Models
  • 1.6 Market Formulation & Validation
  • 1.7 Model Details
    • 1.7.1 Commodity Flow Analysis
      • 1.7.1.1 Approach 1: Commodity flow approach
      • 1.7.1.2 Approach 2: Country wise market estimation using bottom up approach
  • 1.8 Global Market: CAGR Calculation
  • 1.9 List of Secondary Sources
  • 1.10 List of Primary Sources
  • 1.11 Objectives
    • 1.11.1 Objective 1:
    • 1.11.2 Objective 2:
  • 1.12 List of Tables

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Central Nervous System Therapeutics Market Variables, Trends & Scope

  • 3.1 Market Segmentation
  • 3.2 Penetration and Growth Prospect Mapping
  • 3.4 Regulatory Framework
  • 3.5 Pipeline Analysis
  • 3.6 Epidemiology Study

Chapter 4 Central Nervous System Therapeutics Market - Industry Outlook

  • 4.1 Market Driver Analysis
    • 4.1.1 Increasing Prevalence of CNS Disorders
    • 4.1.2 Presence of Strong Pipeline Drugs
    • 4.1.3 Introduction of a Novel Drug Delivery Systems in CNS
  • 4.2 Market Restraint Analysis
    • 4.2.1 High Treatment Cost
    • 4.2.2 Lack of Neurologists and Neurosurgeons

Chapter 5 Business Environment Analysis

  • 5.1 SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
  • 5.2 Porter's Five Forces Analysis

Chapter 6 Competitive Analysis

  • 6.1 Major Deals & Strategic Alliances
  • 6.2 Recent Developments & Impact Analysis, by Key Market Participants
    • 6.2.1 Company/Competition Categorization (Key Innovators, Market Leaders, Expansion)
    • 6.2.3 Innovators
    • 6.2.4 List of Key Distributors and Channel Partners
    • 6.2.5 Key Company Market Share Analysis, 2020
  • 6.3 Public Companies
    • 6.3.1 Company Market Position Analysis
    • 6.3.2 Competitive Dashboard Analysis
  • 6.4 Private Companies
    • 6.4.1 List of Key Emerging Companies /Technology Disruptors/Innovators
    • 6.4.2 Regional Network Map

Chapter 7 Central Nervous System Therapeutics Market - Segment Analysis, By Disease, 2017 - 2028 (USD Million)

  • 7.1 Central Nervous System Therapeutics Market, Disease Outlook Key Takeaways
  • 7.2 Central Nervous System Therapeutics Market: Disease Movement Analysis
  • 7.3 Neurovascular Diseases
    • 7.3.1 Neurovascular Disease Treatment Market, 2017 - 2028 (USD Million)
  • 7.4 Mental Health
    • 7.4.1 Mental Health Treatment Market, 2017 - 2028 (USD Million)
    • 7.4.2 Anxiety Disorders
      • 7.4.2.1 Anxiety Disorders Treatment Market, 2017 - 2028 (USD Million)
    • 7.4.3 Mood disorders
      • 7.4.3.1 Mood Disorder Treatment Market, 2017 - 2028 (USD Million)
    • 7.4.4 Epilepsy
      • 7.4.4.1 Epilepsy Treatment Market, 2017 - 2028 (USD Million)
    • 7.4.5 Psychotic Disorders
      • 7.4.5.1 Psychotic Disorders Treatment Market, 2017 - 2028 (USD Million)
    • 7.4.6 Others
      • 7.4.6.1 Others Market, 2017 - 2028 (USD Million)
  • 7.5 Degenerative Disorders
    • 7.5.1 Degenerative Disorders Treatment Market, 2017 - 2028 (USD million)
    • 7.5.2 Alzheimer's Disease
      • 7.5.2.1 Alzheimer's Disease Treatment Market, 2017 - 2028 (USD Million)
    • 7.5.3 Parkinson's Disease
      • 7.5.3.1 Parkinson's Disease Treatment Market, 2017 - 2028 (USD Million)
    • 7.5.4 Multiple Sclerosis
      • 7.5.4.1 Multiple Sclerosis Treatment Market, 2017 - 2028 (USD Million)
    • 7.5.5 Huntington's Disease
      • 7.5.5.1 Huntington's Disease Treatment Market, 2017 - 2028 (USD Million)
    • 7.5.6 Amyotrophic Lateral Sclerosis
      • 7.5.6.1 Amyotrophic Lateral Sclerosis Treatment Market, 2017 - 2028 (USD Million)
    • 7.5.7 Others
      • 7.5.7.1 Others Treatment Market, 2017 - 2028 (USD Million)
  • 7.6 CNS Trauma
    • 7.6.1 CNS Trauma Treatment Market, 2017 - 2028 (USD Million)
  • 7.7 Infectious Diseases
    • 7.7.1 Infectious Diseases Treatment Market, 2017 - 2028 (USD Million)
  • 7.8 CNS Cancer
    • 7.8.1 Cancer Treatment Market, 2017 - 2028 (USD Million)
  • 7.9 Others
    • 7.9.1 Others Treatment Market, 2017 - 2028 (USD Million)

Chapter 8 Central Nervous System Therapeutics Market- Segment Analysis, By Region, 2017 - 2028 (USD Million)

  • 8.1 Central Nervous System Therapeutics Market: Regional Movement Analysis
  • 8.2 North America
    • 8.2.1 North America, SWOT Analysis
    • 8.2.2 North America Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.2.3 U.S.
      • 8.2.3.1 U.S. Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.2.4 Canada
      • 8.2.4.1 Canada Market Estimates and Forecast, 2017 - 2028 (USD Million)
  • 8.3 Europe
    • 8.3.1 Europe, SWOT Analysis
    • 8.3.2 Europe Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.3.3 Germany
      • 8.3.3.1 Germany Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.3.4 U.K.
      • 8.3.4.1 U.K. Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.3.5 Spain
      • 8.3.5.1 Spain Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.3.6 France
      • 8.3.6.1 France Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.3.7 Italy
      • 8.3.7.1 Italy Market Estimates and Forecast, 2017 - 2028 (USD Million)
  • 8.4 Asia Pacific
    • 8.4.1 Asia Pacific, SWOT Analysis
    • 8.4.2 Asia Pacific Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.4.3 Japan
      • 8.4.3.1 Japan Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.4.4 China
      • 8.4.4.1 China Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.4.5 India
      • 8.4.5.1 India Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.4.6 South Korea
      • 8.4.6.1 South Korea Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.4.8 Australia
      • 8.4.8.1 Australia Market Estimates and Forecast, 2017 - 2028 (USD Million)
  • 8.5 Latin America
    • 8.5.1 Latin America, SWOT Analysis
    • 8.5.2 Latin America Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.5.3 Brazil
      • 8.5.3.1 Brazil Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.5.4 Mexico
      • 8.5.4.1 Mexico Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.5.5 Argentina
      • 8.5.5.1 Argentina Market Estimates and Forecast, 2017 - 2028 (USD Million)
  • 8.6 Middle East & Africa
    • 8.6.1 Middle East & Africa, SWOT Analysis
    • 8.6.2 Middle-East & Africa Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.6.3 South Africa
      • 8.6.3.1 South Africa Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.6.4 Saudi Arabia
      • 8.6.4.1 Saudi Arabia Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.6.5 UAE
      • 8.6.5.1 UAE Market Estimates and Forecast, 2017 - 2028 (USD Million)

Chapter 9 Company Profile

  • 9.1 Company Profiles
    • 9.1.1 Biogen
      • 9.1.1.1 Company overview
      • 9.1.1.2 Financial performance
      • 9.1.1.3 Product benchmarking
      • 9.1.1.4 Strategic initiatives
    • 9.1.2 Otsuka Pharmaceutical Co., Ltd.
      • 9.1.2.1 Company overview
      • 9.1.2.2 Financial performance
      • 9.1.2.3 Product benchmarking
      • 9.1.2.4 Strategic initiatives
    • 9.1.3 Eli Lilly and Company
      • 9.1.3.1 Company overview
      • 9.1.3.2 Financial performance
      • 9.1.3.3 Product benchmarking
      • 9.1.3.4 Strategic initiatives
    • 9.1.4 Merck & Co.
      • 9.1.4.1 Company overview
      • 9.1.4.2 Financial performance
      • 9.1.4.3 Product benchmarking
      • 9.1.4.4 Strategic initiatives
    • 9.1.5 Astra Zeneca
      • 9.1.5.1 Company overview
      • 9.1.5.2 Financial performance
      • 9.1.5.3 Product benchmarking
      • 9.1.5.4 Strategic initiatives
    • 9.1.6 Shire PLC
      • 9.1.6.1 Company overview
      • 9.1.6.2 Financial performance
      • 9.1.6.3 Product benchmarking
      • 9.1.6.4 Strategic initiatives
    • 9.1.7 Novartis AG
      • 9.1.7.1 Company overview
      • 9.1.7.2 Financial performance
      • 9.1.7.3 Product benchmarking
      • 9.1.7.4 Strategic initiatives
    • 9.1.8 Teva Pharmaceutical Industries Ltd.
      • 9.1.8.1 Company overview
      • 9.1.8.2 Financial performance
      • 9.1.8.3 Product benchmarking
      • 9.1.8.4 Strategic initiatives
    • 9.1.9 Johnson & Johnson Services, Inc.
      • 9.1.9.1 Company overview
      • 9.1.9.2 Financial performance
      • 9.1.9.3 Product benchmarking
      • 9.1.9.4 Strategic initiatives
    • 9.1.11 Pfizer, Inc.
      • 9.1.11.1 Company overview
      • 9.1.11.2 Financial performance
      • 9.1.11.3 Product benchmarking
      • 9.1.11.4 Strategic initiatives
Back to Top
전화 문의
F A Q